biostudies-literatureZhang ACAMS Innovation Fund for Medical SciencesNational Natural Science Foundation of China154https://www.ebi.ac.uk/biostudies/studies/S-EPMC11228008biostudies-literatureUnknown24(1)Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are Philadelphia chromosome-negative myeloproliferative neoplasms. These conditions share overlapping clinical presentations; however, their prognoses differ significantly. Current morphological diagnostic methods lack reliability in subtype differentiation, underlining the need for improved diagnostics. The aim of this study was to investigate the multi-omics alterations in bone marrow biopsies of patients with ET and pre-PMF to improve our understanding of the nuanced diagnostic characteristics of both diseases. We performed proteomic analysis with 4D direct data-independent acquisition and microbiome analysis with 2bRAD-M sequencing technology to identify differential protein and microbe levels between untreaClinical and experimental medicineMulti-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.PMC1122800882000136822701522023-I2M-QJ-01582100151Fu RXue FLi HChen JGu WSun TYu DZhang LLiu WDai XLiu XDong HWang WYang RChen YJu MChi YZhang AfalseMulti-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are Philadelphia chromosome-negative myeloproliferative neoplasms. These conditions share overlapping clinical presentations; however, their prognoses differ significantly. Current morphological diagnostic methods lack reliability in subtype differentiation, underlining the need for improved diagnostics. The aim of this study was to investigate the multi-omics alterations in bone marrow biopsies of patients with ET and pre-PMF to improve our understanding of the nuanced diagnostic characteristics of both diseases. We performed proteomic analysis with 4D direct data-independent acquisition and microbiome analysis with 2bRAD-M sequencing technology to identify differential protein and microbe levels between untrea2024-01-01T00:00:00Z2024 Jul2025-04-26T05:42:14.143Z2025-04-06T11:35:24.609ZS-EPMC112280083897295210.1007/s10238-024-01350-y